



PRESS RELEASE

Published: 04-02-2020

SAVE THE DATE: Asarina Pharma R&D Day - Thursday 26 March

CORRECTION: Asarina Pharma AB (publ) (ASAP: FN Stockholm) invites institutional investors, financial analysts and media to an R&D Day in Stockholm on THURSDAY 26 MARCH 2020 (not Weds 26 March as published earlier 0700 UTC, 4 February.)

Presentations will be held by CEO Peter Nordkild, founder and Chief Science Officer Professor Torbjörn Bäckström, as well as other leading experts in the field. The aim of the day is to increase understanding of Asarina Pharma's research into PMDD, menstrual migraine and Tourette syndrome.

The R&D Day will be held at Helio GT30, Grev Turegatan 30 in Stockholm from 14.00-17.00 on Thursday 26th March.

Please register for the R&D Day by following this link:
https://financialhearings.com/event/12602/register/live_event

A formal invitation including a full program for the event will be sent out and will also be available at www.asarinapharma.com

We look forward to meeting you!

This information was provided by Asarina Pharma AB (publ) for publishing on February 4, 2020 at 17.00 CET.

For further information, please contact:

Peter Nordkild, CEO Asarina Pharma AB

Tel: +45 25 47 16 46

Email: peter.nordkild@asarinapharma.com

About Asarina Pharma

Asarina Pharma is a Swedish biotech company developing Sepranolone, the world's first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years' research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSAs compounds (GABA_A Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading women's health company.